Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gege Gui

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid LeukemiaGege Gui, Christopher S Hourigan
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2019
Heterogeneity in refractory acute myeloid leukemiaSachi Horibata, Gege Gui, Justin Lack, et al.
Cancer Research|April 29, 2021
EGFR Activates a TAZ-Driven Oncogenic Program in GlioblastomaMinling Gao, Yi Fu, Weiqiang Zhou, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Molecular Cancer Therapeutics|March 16, 2021
Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem CellsYingchao Xue, Yi Fu, Fenghong Zhao, et al.
JCI Insight|December 7, 2018
Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometryKarolyn A Oetjen, Katherine E Lindblad, Meghali Goswami, et al.
Leukemia|June 18, 2024
Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillanceNicholas McCarthy, Gege Gui, Florent Dumezy, et al.
Molecular Neurodegeneration|January 11, 2022
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cellsQian Li, Yi Feng, Yingchao Xue, et al.
Neuron|February 5, 2026
C9orf72 hexanucleotide repeat RNA drives transcriptional dysregulation through genome-wide DNA:RNA hybrid G-quadruplexesHonghe Liu, Mingming Liu, Yang Liu, et al.
Haematologica|May 28, 2026
Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysisJesse M Tettero, Mei-Jie Zhang, Wentong Liu, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid LeukemiaGege Gui, Christopher S Hourigan
Proceedings of the National Academy of Sciences of the United States of America|May 9, 2019
Heterogeneity in refractory acute myeloid leukemiaSachi Horibata, Gege Gui, Justin Lack, et al.
Cancer Research|April 29, 2021
EGFR Activates a TAZ-Driven Oncogenic Program in GlioblastomaMinling Gao, Yi Fu, Weiqiang Zhou, et al.
Medrxiv : the Preprint Server for Health Sciences|September 4, 2023
Persistent <i>IDH</i> mutations are not associated with increased relapse or death in patients with <i>IDH</i>-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplant with post-transplant cyclophosphamideNiveditha Ravindra, Laura W Dillon, Gege Gui, et al.
Molecular Cancer Therapeutics|March 16, 2021
Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem CellsYingchao Xue, Yi Fu, Fenghong Zhao, et al.
JCI Insight|December 7, 2018
Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometryKarolyn A Oetjen, Katherine E Lindblad, Meghali Goswami, et al.
Leukemia|June 18, 2024
Pre-emptive detection and evolution of relapse in acute myeloid leukemia by flow cytometric measurable residual disease surveillanceNicholas McCarthy, Gege Gui, Florent Dumezy, et al.
Molecular Neurodegeneration|January 11, 2022
Edaravone activates the GDNF/RET neurotrophic signaling pathway and protects mRNA-induced motor neurons from iPS cellsQian Li, Yi Feng, Yingchao Xue, et al.
Neuron|February 5, 2026
C9orf72 hexanucleotide repeat RNA drives transcriptional dysregulation through genome-wide DNA:RNA hybrid G-quadruplexesHonghe Liu, Mingming Liu, Yang Liu, et al.
Haematologica|May 28, 2026
Real-world heterogeneity in the prognostic value of pre-transplant flow cytometry measurable residual disease in acute myeloid leukemia in first complete remission: CIBMTR analysisJesse M Tettero, Mei-Jie Zhang, Wentong Liu, et al.
Pageof 3